about
Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections.Spontaneous pyogenic facet joint infection.Long-term clinical and radiological magnetic resonance imaging outcome of abscess-associated spontaneous pyogenic vertebral osteomyelitis under conservative management.Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitisPyogenic arthritis of native joints due to Bacteroides fragilis: Case report and review of the literatureNeurosarcoidosis: report of 30 cases and a literature survey.Risk factors and prognosis of vertebral compressive fracture in pyogenic vertebral osteomyelitis.Streptococcal vertebral osteomyelitis: multiple faces of the same disease.Clinical findings of bacteremic septic arthritis according to the site of acquisition: The overlap between health care-related and community- and nosocomial-acquired cases.Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by meticillin-susceptible Staphylococcus aureus.Pyogenic arthritis of native joints in non-intravenous drug users: A detailed analysis of 268 cases attended in a tertiary hospital over a 22-year period.The changing epidemiology of bacteraemic osteoarticular infections in the early 21st century.Shorter treatments for vertebral osteomyelitis.Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureusClinical and microbiological findings in prosthetic joint replacement due to aseptic loosening.Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.Infected hip hemiarthroplasties and total hip arthroplasties: Differential findings and prognosis.Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureusEfficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Editorial Commentary: Pyogenic Vertebral Osteomyelitis and Antimicrobial Therapy: It's Not Just the Length, but Also the Choice.Erratum for El Haj et al., Comparative Efficacies of Cloxacillin-Daptomycin and the Standard Cloxacillin-Rifampin Therapies against an Experimental Foreign-Body Infection by Methicillin-Susceptible Staphylococcus aureus.RNAIII inhibiting peptide against foreign-body infection by methicillin-resistant Staphylococcus aureusA Large Multicenter Study of Methicillin–Susceptible and Methicillin–Resistant Staphylococcus aureus Prosthetic Joint Infections Managed With Implant RetentionFatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patientThe role of intraoperative cultures at the time of reimplantation in the management of infected total joint arthroplastyThe Impact of Gram-Negative Bacilli in Bacteremic Skin and Soft Tissue Infections Among Patients With Diabetes
P50
Q35694058-8E3D366E-B60C-49DB-ADB9-3E1C7DA6AD56Q36449714-D3C67A42-4060-4B11-AF68-116766F1E276Q37022498-222B9B50-914C-4D28-ABB5-3878380FC273Q37204174-2E152B24-B40D-4FB4-B05C-2A5623D57953Q37205194-CD7569F4-8430-4EB0-8922-9C6C3745357DQ37954892-00545653-81D3-4433-BA6F-06C4DD84301BQ38517649-A99F7614-4F01-4613-B3E7-74DAAE3373ADQ40240126-DC944A00-9148-42CC-99D7-64585867AA54Q40240738-B942AFBF-4F52-484D-8163-BB512EE3C8C0Q40975034-40C9CC46-6E20-41CA-B73C-FC6EF8A6C7A7Q41177938-D1368A71-17DD-4470-BC81-93BA5CC5EA6EQ41433706-15A5A2FB-1A73-4D93-A054-8983BF3263F9Q41523712-A3AB1292-A657-4861-BB15-CB3539DF8F8CQ41622237-CC76A7B7-4E01-430F-8D78-C0D3E634382BQ42008069-05B3AC5F-22E6-40ED-8103-2C667236E971Q42036509-AA84B992-0F21-4534-B8C3-72EEC64407DDQ42209248-988EB7FB-6DBD-49CB-94DE-063A7884772FQ42213783-93E652EE-4508-445C-A430-07DF605205D8Q42215035-AAF9636B-073F-4ABF-8DB5-0911BF047B7EQ42251660-E0D7EAE7-9FE0-4D1C-965A-433CF672E41BQ42529961-374C3406-1A3F-445B-BCC3-3F490287AF6EQ42586714-348B8EDC-3687-471E-8574-CE93FCEA21A6Q53795470-BEB43E44-09BD-4DE4-AD1E-197085569FC2Q55395030-8A6AA530-E4E8-4E39-8D64-1EE8CB1F5472Q57611747-CB17781A-EDEB-4CF3-9268-56DC27A66CBFQ61704552-B3C6BD4E-8E88-4890-84AC-9C0D85F88C9AQ63880911-F1D549FF-4060-42E8-A1C8-FCF405FF52ADQ81138666-75BD1CD0-4030-46D1-B592-885DE40AC49BQ92916230-00EAF498-23E1-4539-AD04-BFA4F84F7B26
P50
description
researcher (ORCID 0000-0001-5776-8422)
@en
name
Oscar Murillo
@en
type
label
Oscar Murillo
@en
prefLabel
Oscar Murillo
@en
P31
P496
0000-0001-5776-8422